JP2009525046A5 - - Google Patents

Download PDF

Info

Publication number
JP2009525046A5
JP2009525046A5 JP2008553336A JP2008553336A JP2009525046A5 JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5 JP 2008553336 A JP2008553336 A JP 2008553336A JP 2008553336 A JP2008553336 A JP 2008553336A JP 2009525046 A5 JP2009525046 A5 JP 2009525046A5
Authority
JP
Japan
Prior art keywords
factor
kinase
synuclein
activity
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008553336A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009525046A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/002685 external-priority patent/WO2007089862A2/en
Publication of JP2009525046A publication Critical patent/JP2009525046A/ja
Publication of JP2009525046A5 publication Critical patent/JP2009525046A5/ja
Pending legal-status Critical Current

Links

JP2008553336A 2006-01-31 2007-01-30 アルファ−シヌクレインキナーゼ Pending JP2009525046A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76400006P 2006-01-31 2006-01-31
PCT/US2007/002685 WO2007089862A2 (en) 2006-01-31 2007-01-30 Alpha-synuclein kinase

Publications (2)

Publication Number Publication Date
JP2009525046A JP2009525046A (ja) 2009-07-09
JP2009525046A5 true JP2009525046A5 (https=) 2010-04-08

Family

ID=38328036

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008553336A Pending JP2009525046A (ja) 2006-01-31 2007-01-30 アルファ−シヌクレインキナーゼ

Country Status (5)

Country Link
US (3) US7553639B2 (https=)
EP (1) EP1989330A4 (https=)
JP (1) JP2009525046A (https=)
CA (1) CA2641219A1 (https=)
WO (1) WO2007089862A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553639B2 (en) 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
EP2247748A2 (en) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synuclein kinase
PT2282758T (pt) * 2008-04-29 2019-02-12 Bioarctic Ab Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína
MX2011009807A (es) * 2009-03-19 2011-09-29 Medical Res Council Technology Compuestos.
CA2789963C (en) 2010-02-26 2019-09-03 Bioarctic Neuroscience Ab Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies
EP2426202A1 (en) * 2010-09-03 2012-03-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Kinases as targets for anti-diabetic therapy
US9458463B2 (en) 2010-09-03 2016-10-04 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Method for treatment of diabetes by a small molecule inhibitor for GRK5
WO2014132249A1 (en) 2013-02-26 2014-09-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method for the assay of synucleins
WO2018057782A1 (en) * 2016-09-23 2018-03-29 University Of Utah Research Foundation Methods of preventing stem cell differentiation using a pask inhibitor
CN110506057B (zh) 2017-02-17 2023-09-29 百时美施贵宝公司 Alpha突触核蛋白抗体及其应用
EP3765855A1 (en) 2018-03-14 2021-01-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd Detection of phospho-serine 129 alpha-synuclein in blood cells as a biomarker for synucleinopathies
RS66984B1 (sr) 2020-06-26 2025-07-31 Bioarctic Ab Antitela koja vezuju alfa-sinuklein protofibril
CN114601928B (zh) * 2022-04-02 2023-03-17 首都医科大学 一种钙超载介导神经元死亡的标志物及应用
CN115569202A (zh) * 2022-10-19 2023-01-06 苏州捷乐思生物科技有限公司 一种帕金森综合征动物模型、药物筛选方法及治疗药物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001238612A1 (en) * 2000-02-18 2001-08-27 The Regents Of The University Of California Method for screening for anti-amyloidogenic properties and method for treatment of neurodegenerative disease
JP2004502781A (ja) * 2000-07-07 2004-01-29 パナシア ファーマシューティカルズ インコーポレーテッド 神経組織の損傷を予防するため、およびα−シヌクレイン疾患を処置するための方法
JP2005538048A (ja) * 2002-05-03 2005-12-15 シエーリング アクチエンゲゼルシャフト チアゾリジノン類、それらの生成及び医薬剤としての使用
WO2004069175A2 (en) * 2003-02-02 2004-08-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER α-SYNUCLEINOPATHIES
US6861422B2 (en) * 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7566548B2 (en) * 2004-08-13 2009-07-28 University Of Massachusetts Methods for identifying therapeutic agents and for treating disease
US20060074088A1 (en) * 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
EP1827473A4 (en) 2004-12-01 2009-08-19 Whitehead Biomedical Inst MODULATOR OF ALPHA SYNNUCLEINE TOXICITY
MX2007007245A (es) * 2004-12-15 2008-02-25 Bayer Schering Pharma Ag Tiazolidinonas metasustituidas, su preparacion y su uso como medicamento.
DE102005005395A1 (de) * 2005-02-03 2006-08-10 Schering Aktiengesellschaft Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
DE102005020104A1 (de) * 2005-04-25 2006-10-26 Schering Ag Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel
US9018003B2 (en) * 2005-05-13 2015-04-28 Whitehead Institute For Biomedical Research Modulators of alpha-synuclein toxicity
US8017781B2 (en) * 2005-11-15 2011-09-13 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
CN101336244B (zh) * 2005-12-08 2011-11-30 雅培制药有限公司 用作蛋白激酶抑制剂的9元杂二环化合物
TW200801008A (en) * 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
US7553639B2 (en) 2006-01-31 2009-06-30 Elan Pharma International Limited Alpha-synuclein kinase
EP2247748A2 (en) * 2008-02-13 2010-11-10 Elan Pharma International Limited Alpha-synuclein kinase

Similar Documents

Publication Publication Date Title
JP2009525046A5 (https=)
Seifert et al. The influence of fundamental traits on mechanisms controlling appendage regeneration
Bahi et al. Dopamine transporter (DAT) knockdown in the nucleus accumbens improves anxiety-and depression-related behaviors in adult mice
Fiorentini et al. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice
Von Koch et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice
Hasegawa et al. Distinct and Cooperative Functions for the Protocadherin-α,-β and-γ Clusters in Neuronal Survival and Axon Targeting
Sennvik et al. Tau‐4R suppresses proliferation and promotes neuronal differentiation in the hippocampus of tau knockin/knockout mice
JP2003517580A5 (https=)
WO2017172733A1 (en) Anti-ryk antibodies and methods of using the same
CN114286710A (zh) 治疗亨廷顿病的方法和材料
CN110628814B (zh) 基于基因编辑技术增加smn蛋白表达的方法及其在sma治疗中的应用
Rahman et al. Early postnatal lead exposure induces tau phosphorylation in the brain of young rats
CN101942463B (zh) 一种建立急性多型性卟啉病转基因小鼠模型的方法
EP1221283A3 (en) Transgenic animal for screening therapeutic agents for brain tumors
CN108719145B (zh) 一种用于筛选治疗帕金森病药物的斑马鱼模型构建方法
CN118421703B (zh) 一种自发出现情绪异常波动的非人哺乳动物模型的构建方法及其用途
WO2006026478A3 (en) Compositions and methods for improving heart function
KR100734815B1 (ko) Htau24 유전자를 발현하는 형질전환 치매 마우스 및 그제조방법
Götz et al. Human tau transgenic mice: towards an animal model for neuro-and glialfibrillary lesion formation
KR100635865B1 (ko) App/c-105 돌연변이 유전자를 발현하는 형질전환 치매마우스
US20060134659A1 (en) Method for demethylating target methylated region of genome DNA
Patil Effects of Ablation of Fibroblasts on the Structure and Function of Salivary Gland
KR101444297B1 (ko) Cyp4f16 유전자가 넉다운된 형질전환마우스 및 그 제조방법
US20130047273A1 (en) Genetically altered animal specimen and related methods
KR100635878B1 (ko) hNCTm 유전자를 발현하는 형질전환 치매 마우스